Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

2005, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins, Lancet, 366, 1267, 10.1016/S0140-6736(05)67394-1 2008, Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis, Lancet, 371, 117, 10.1016/S0140-6736(08)60104-X Armitage, 2007, The safety of statins in clinical practice, Lancet, 370, 1781, 10.1016/S0140-6736(07)60716-8 Ridker, 2008, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein, N Engl J Med, 359, 2195, 10.1056/NEJMoa0807646 Freeman, 2001, Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study, Circulation, 103, 357, 10.1161/01.CIR.103.3.357 Keech, 2003, Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose—results from the LIPID trial, Diabetes Care, 26, 2713, 10.2337/diacare.26.10.2713 Sever, 2003, Lancet, 361, 1149, 10.1016/S0140-6736(03)12948-0 Collins, 2003, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial, Lancet, 361, 2005, 10.1016/S0140-6736(03)13636-7 Kjekshus, 2007, Rosuvastatin in older patients with systolic heart failure, N Engl J Med, 357, 2248, 10.1056/NEJMoa0706201 Yusuf, 2009, Lipid lowering for primary prevention, Lancet, 373, 1152, 10.1016/S0140-6736(09)60357-3 Shepherd, 2002, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial, Lancet, 360, 1623, 10.1016/S0140-6736(02)11600-X Nakamura, 2006, Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial, Lancet, 368, 1155, 10.1016/S0140-6736(06)69472-5 2002, Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT), JAMA, 288, 2998, 10.1001/jama.288.23.2998 1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet, 344, 1383 Tavazzi, 2008, Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial, Lancet, 372, 1231, 10.1016/S0140-6736(08)61240-4 2000, Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge?, Ital Heart J, 1, 810 Downs, 1998, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study, JAMA, 279, 1615, 10.1001/jama.279.20.1615 Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629 Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators, N Engl J Med, 335, 1001, 10.1056/NEJM199610033351401 Amarenco, 2006, High-dose atorvastatin after stroke or transient ischemic attack, N Engl J Med, 355, 549, 10.1056/NEJMoa061894 Serruys, 2002, Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial, JAMA, 287, 3215, 10.1001/jama.287.24.3215 1999 Nakata, 2006, Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control, Diabetologia, 49, 1881, 10.1007/s00125-006-0269-5 Zeggini, 2007, Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes, Science, 316, 1336, 10.1126/science.1142364 Lyssenko, 2008, Clinical risk factors, DNA variants, and the development of type 2 diabetes, N Engl J Med, 359, 2220, 10.1056/NEJMoa0801869 Lalli, 2008, Statin modulates insulin signaling and insulin resistance in liver and muscle of rats fed a high-fat diet, Metabolism, 57, 57, 10.1016/j.metabol.2007.07.021 Takagi, 2008, Effect of pravastatin on the development of diabetes and adiponectin production, Atherosclerosis, 196, 114, 10.1016/j.atherosclerosis.2007.02.013 Sugiyama, 2007, Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease, Atherosclerosis, 194, e43, 10.1016/j.atherosclerosis.2006.08.023 Gannage-Yared, 2005, Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients, Metabolism, 54, 947, 10.1016/j.metabol.2005.02.011 Costa, 2003, Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose, Diabet Med, 20, 743, 10.1046/j.1464-5491.2003.00993.x Szendroedi, 2009, Effects of high-dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in nonobese type 2 diabetic patients, Diabetes Care, 32, 209, 10.2337/dc08-1123 Sattar, 2008, Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities?, Diabetologia, 51, 926, 10.1007/s00125-008-0954-7 Sabatine, 2004, High-dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 substudy, Circulation, 110, 834 Shepherd, 2006, Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes. The treating to new targets (TNT) study, Diabetes Care, 29, 1220, 10.2337/dc05-2465 Athyros, 2002, Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study, Curr Med Res Opin, 18, 220, 10.1185/030079902125000787 Koren, 2004, Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study, J Am Coll Cardiol, 44, 1772 1997, The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts, N Engl J Med, 336, 153, 10.1056/NEJM199701163360301